C-A3TNHemostemix
autologous stem cells, angiogenic cell precursors, ischemia
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-A3TN
C-A3TNC-A3TNautologous stem cells, angiogenic cell precursors, ischemia
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Hemostemix stated that it was a clinical-stage Canadian-Israeli biotechnology company focused on developing and commercializing innovative blood-derived cell therapies for unmet medical conditions, indicating a belief that such therapies could serve as a meaningful treatment approach where existing options were insufficient.
SourceHemostemix states that it is a clinical-stage Canadian-Israeli company focused on developing and commercializing innovative blood-derived cell therapies for medical conditions that are not adequately addressed by current treatments.
SourceHemostemix presented itself as a public clinical-stage biotechnology company focused on developing and commercializing innovative blood-derived cell therapies for medical conditions that it believed were not adequately addressed by existing treatments.
SourceHemostemix states that healthcare should be personal, that a patient's own body can provide the source of therapy, and that regenerative medicine can shape the future of care if it is delivered safely and effectively. The company presents its platform as an evidence-based cell therapy approach with potential across multiple ischemic diseases, including restoring blood flow to ischemic limbs.
Source